Summary of Findings for the Main Comparison [Explanation].
HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV-infected adults (Mosam 2012) – RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi's sarcoma
Settings: Durban, South Africa
Intervention: HAART + ABV
Comparison: HAART alone
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | Comments | |
|---|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | |||||
| HAART alone | HAART + ABV | |||||
| Mortality | 240 per 1000 | 221 per 1000 (108 to 451) | RR 0.92 (0.45 to 1.88) | 100 (1 study) | ⊕⊕⊕◯ moderate1 | |
| Progressive disease | 200 per 1000 | 20 per 1000 (2 to 150) | RR 0.1 (0.01 to 0.75) | 100 (1 study) | ⊕⊕⊕◯ moderate1 | |
| Clinical response - complete response | 80 per 1000 | 160 per 1000 (51 to 498) | RR 2 (0.64 to 6.22) | 100 (1 study) | ⊕⊕⊕◯ moderate1 | |
| Clinical response - partial response | 280 per 1000 | 479 per 1000 (283 to 815) | RR 1.71 (1.01 to 2.91) | 100 (1 study) | ⊕⊕⊕◯ moderate1 | |
| Clinical response - stable disease | 160 per 1000 | 10 per 1000 (0 to 158) | RR 0.06 (0 to 0.99) | 100 (1 study) | ⊕⊕⊕◯ moderate1 | |
| Clinical response - overall response (complete and partial) | 360 per 1000 | 641 per 1000 (418 to 979) | RR 1.78 (1.16 to 2.72) | 100 (1 study) | ⊕⊕⊕◯ moderate1 | |
| Adverse events Follow-up: mean 12 months | 520 per 1000 | 458 per 1000 (307 to 686) | RR 0.88 (0.59 to 1.32) | 100 (1 study) | ⊕⊕⊕◯ moderate1 | |
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
ABV: doxorubicin, bleomycin and vincristine; CI: confidence interval; HAART: highly active antiretroviral therapy; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
There were very few events with very wide confidence intervals.